10:58 AM
 | 
Oct 25, 2018
 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis

Patient sample, cell culture and mouse studies suggest inhibiting STAT3 or immune checkpoint inhibitors could help treat idiopathic pulmonary fibrosis (IPF) or sarcoidosis-associated pulmonary fibrosis. In IPF patients, lung levels of PD-1 and peripheral blood mononuclear cell (PBMC) levels of its downstream effector STAT3 were higher than in samples from healthy volunteers, and high PBMC STAT3 levels were associated with poor transplant-free survival. In...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >